SAGE Therapeutics Inc (SAGE.OQ)
141.19USD
24 Apr 2018
$-4.30 (-2.96%)
$145.49
$146.17
$146.75
$140.99
151,737
216,706
$195.97
$59.59
Mon, Apr 23 2018
BRIEF-Sage Therapeutics Submits New Drug Application To U.S. FDA For Intravenous Brexanolone In The Treatment Of Postpartum Depression
* SAGE THERAPEUTICS SUBMITS NEW DRUG APPLICATION TO U.S. FDA FOR INTRAVENOUS BREXANOLONE IN THE TREATMENT OF POSTPARTUM DEPRESSION
BRIEF-Sage Therapeutics Qtrly Net Loss Per Share $1.75
* SAGE THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES PIPELINE UPDATE
BRIEF-Sage Therapeutics Prices Public Offering Of 3.5 Mln Shares At $164/Share
* PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 3.5 MILLION SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $164.00 PER SHARE Source text for Eikon: Further company coverage:
BRIEF-Sage Therapeutics Announces Proposed Public Offering Of Common Stock
* SAGE THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK
BRIEF-Sage Therapeutics Receives FDA Breakthrough Therapy Designation For Sage-217
* SAGE THERAPEUTICS RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR SAGE-217 FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER
BRIEF-Sage Therapeutics Says Sage-217 Met Primary Endpoint Of Improved Sleep Efficiency In Phase 1/2 Study
* SAGE THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM PLACEBO-CONTROLLED TRIAL IN A MODEL OF INSOMNIA DEMONSTRATING ACTIVITY ON SLEEP PARAMETERS AND SUPPORTING DEVELOPMENT OF SAGE-217 AS POTENTIAL TREATMENT FOR SLEEP DISORDERS
Sage shares surge as depression drug succeeds in mid-stage trial
Drug developer Sage Therapeutics Inc's shares soared as much as 85 percent to a record high on Thursday after its experimental drug to reduce the symptoms of depression succeeded in a mid-stage trial.
UPDATE 3-Sage shares surge as depression drug succeeds in mid-stage trial
* Shares surge as much as 85 pct (Adds details on drug's mechanism, analyst comment, updates shares)
Sage's depression drug succeeds in mid-stage study
Dec 7 Sage Therapeutics Inc said on Thursday its drug to treat patients with moderate to severe depression met the main goal in a mid-stage study.
BRIEF-Sage Therapeutics prices public offering of 3.53 mln common shares at $85/share
* SAYS PUBLIC OFFERING OF 3.53 MILLION COMMON SHARES PRICED AT $85.00PER SHARE Source text for Eikon: Further company coverage: